Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification

Ovarian cancer (OC) accounts for approximately 4% of cancer deaths in women worldwide and is the deadliest gynecologic malignancy. High-grade serous ovarian cancer (HGSOC) is the most predominant ovarian cancer, in which BRCA1/2 gene mutation ranges from 3 to 27%. PARP inhibitors (PARPi) have shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasimli, Khayal, Raab, Monika, Tahmasbi Rad, Morva, Kurunci-Csacsko, Elisabeth, Becker, Sven, Strebhardt, Klaus, Sanhaji, Mourad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502276/
https://www.ncbi.nlm.nih.gov/pubmed/36142803
http://dx.doi.org/10.3390/ijms231810892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502276/
https://www.ncbi.nlm.nih.gov/pubmed/36142803
http://dx.doi.org/10.3390/ijms231810892

Ejemplares similares